INTRODUCTION:

The pharmaceutical industry faces a significant challenge in formulating effective drug products from compounds that are poorly water-soluble. As the development of new drug molecules continues to rise, a growing number of active pharmaceutical ingredients (APIs) fall under Biopharmaceutical Classification System (BCS) Class II and IV, characterized by low solubility. This limited aqueous solubility often results in poor dissolution rates and inadequate bioavailability when administered orally, thereby reducing the drug’s therapeutic efficacy.

Bioavailability refers to the proportion of a drug that enters systemic circulation in an active form and is available at the site of action. For oral drug delivery, bioavailability is influenced primarily by two parameters: solubility and permeability. While permeability can be optimized through chemical modification and formulation strategies, poor solubility remains a major bottleneck in drug development. A drug that does not dissolve effectively in gastrointestinal fluids may pass through the digestive system without being absorbed, regardless of its pharmacological potential.

Various physicochemical and formulation-based strategies have been developed to overcome solubility-related challenges. These include particle size reduction (micronization and nanonization), solid dispersion techniques, the use of surfactants, complexation with cyclodextrins, and lipid-based drug delivery systems. Each of these strategies is designed to increase the surface area of the drug exposed to the dissolution medium, improve wettability, or enhance drug solubility through molecular interactions with excipients or carriers.

One of the most straightforward and widely used methods is particle size reduction. By decreasing the particle size of a drug, the surface area available for dissolution increases, leading to faster drug release. However, this technique has limitations, especially for drugs with high crystallinity or those that tend to agglomerate. Nanotechnology-based approaches, such as nanocrystals and nanosuspensions, offer more advanced and stable solutions by enabling greater control over particle size and dispersion.

Another promising strategy is the formation of solid dispersions, where the poorly soluble drug is dispersed in a hydrophilic carrier matrix. This technique not only enhances dissolution but can also convert the drug into an amorphous form, which generally has higher solubility compared to its crystalline counterpart. However, challenges related to physical and chemical stability must be addressed for long-term storage and efficacy.

Factors affecting the bioavailability of drug:

The solubility and absorption of a drug are critical factors that influence its bioavailability and therapeutic effectiveness. Factors affect these processes are

1. Physicochemical Properties of the Drug: Solubility is primarily influenced by the drug’s chemical structure, polarity, and molecular size. Hydrophilic (water-soluble) drugs dissolve more easily in aqueous body fluids, while lipophilic (fat-soluble) drugs may require lipid-based formulations to enhance solubility. The pKa of the drug and the pH of the environment also play crucial roles, especially in ionizable drugs, as only the unionized form can readily cross biological membranes.

2. Formulation Factors: The physical form of the drug (solid, liquid, or suspension), particle size, and the use of excipients (e.g., surfactants, solubilizers) can significantly impact solubility and absorption. Smaller particle sizes increase surface area, enhancing dissolution rate and, consequently, absorption.

3. Gastrointestinal (GI) Environment: The pH, presence of enzymes, and motility within different regions of the GI tract influence both solubility and absorption. For example, weakly acidic drugs tend to be better absorbed in the stomach, whereas weak bases are more readily absorbed in the intestines.

4. Drug Transport Mechanisms: Passive diffusion is the most common mode of absorption, but some drugs rely on active transport or facilitated diffusion, which can be affected by saturation and competition with other substances.

5. First-pass Metabolism: Although not directly affecting solubility, extensive metabolism in the liver after absorption can reduce the effective drug concentration, impacting overall bioavailability.

Strategies for Enhancing Bioavailability:

1. Particle Size Reduction Techniques:

Reducing the particle size of a drug increases its surface area, enhancing the dissolution rate per the Noyes-Whitney equation. Micronization and nanosuspensions are common techniques. Micronized drugs are produced via milling, while nanosuspensions involve wet milling or high-pressure homogenization. These techniques have been shown to improve the bioavailability of drugs like fenofibrate and griseofulvin.

2. Solid Dispersions:

Solid dispersions involve dispersing the drug in an inert carrier at the solid state, often improving wettability and reducing crystallinity. Carriers such as PEG, PVP, and HPMC are commonly used. This method has demonstrated success in enhancing bioavailability for drugs like itraconazole and ritonavir (Khan et al., 2022).

3. Lipid-Based Drug Delivery Systems:

Lipid-based formulations such as self-emulsifying drug delivery systems (SEDDS), liposomes, and solid lipid nanoparticles enhance solubility by dissolving the drug in lipids, promoting lymphatic transport. This approach is effective for lipophilic drugs like cyclosporine A and saquinavir.

4. Cyclodextrin Complexation:

Cyclodextrins are cyclic oligosaccharides that form inclusion complexes with hydrophobic drugs, improving solubility and stability. β-Cyclodextrin and hydroxypropyl-β-cyclodextrin are commonly used. This strategy has enhanced the solubility of drugs like dexamethasone and hydrocortisone.

5. Use of Surfactants and Solubilizers:

Surfactants reduce surface tension and enhance wetting, leading to improved solubilization. Commonly used surfactants include polysorbates, sodium lauryl sulfate, and cremophor. These agents are often incorporated in formulations of paclitaxel and docetaxel to enhance their aqueous solubility.

6. Prodrug Approach:

The prodrug approach involves chemically modifying a poorly soluble drug into a more soluble derivative, which is converted to the active drug in vivo. This strategy is used in drugs like valacyclovir (prodrug of acyclovir) and enalapril (prodrug of enalaprilat).

7. Nanotechnology-Based Approaches:

Nanoparticles, dendrimers, and polymeric micelles offer advanced methods to enhance bioavailability. These systems increase surface area and improve drug stability. Nanotechnology is especially useful for targeting and controlled release applications.

Evaluation Techniques:

In vitro dissolution studies are used to measure the rate and extent of drug release in simulated gastrointestinal fluids, providing insight into how the drug will dissolve and be absorbed. Solubility testing evaluates the drug’s solubility in various solvents or surfactants to determine which enhances dissolution. Bioavailability studies, typically through pharmacokinetic assessments in animals or humans, measure absorption and plasma concentrations. Particle size analysis examines the impact of reducing particle size on drug dissolution, while stability testing evaluates formulation stability under different conditions. Additionally, microscopy is used to visualize changes in drug morphology, such as the formation of nanoparticles or amorphous forms, which can influence bioavailability. These evaluation techniques collectively offer a comprehensive understanding of the effectiveness of bioavailability enhancement strategies.

Recent Advertisement and Future Prospective:

Recent advancements in enhancing the bioavailability of poorly soluble drugs have focused on innovative delivery systems such as lipid-based formulations, nanotechnology, and amorphous solid dispersions. These approaches, actively promoted by pharmaceutical companies and showcased in industry events, significantly improve solubility and absorption. Cyclodextrin complexes and 3D printed dosage forms also show promising results. Looking ahead, the integration of AI in formulation design, personalized nanomedicine, and the development of smart polymers are expected to revolutionize drug delivery. Emphasis on green and sustainable technologies will further shape future strategies, making treatments more effective, targeted, and environmentally friendly.

CONCLUSION:

In conclusion, improving the bioavailability of poorly soluble drugs is a critical challenge in pharmaceutical development. A variety of formulation strategies have been established, each targeting specific physicochemical and biological barriers to enhance solubility and absorption. Techniques such as particle size reduction, solid dispersions, lipid-based systems, cyclodextrin complexation, surfactant use, prodrug modifications, and nanotechnology have demonstrated significant potential in increasing the therapeutic efficacy of low-solubility drugs. These methods not only improve dissolution but also enhance stability and targeted delivery. Regulatory considerations, scalability, and patient-centric design play crucial roles in translating these technologies into viable products. Recent innovations like 3D printing and personalized medicine further expand the scope of bioavailability enhancement. Ultimately, selecting an optimal strategy requires a tailored approach based on the drug’s properties, intended use, and patient needs. Continued research and interdisciplinary collaboration will be key to overcoming current limitations and advancing the field toward more effective and accessible drug therapies.

REFERENCES:

1. Kalepu S, Nekkanti V. Biopharmaceutical classification system and solubility enhancement technologies: An overview. Acta Pharm Sin B. 2021; 11(2):39–49.

2. Khan AW, Kotta S, Ansari SH, Ali J. Formulation development and optimization of solid dispersions to improve solubility of poorly water-soluble drugs. Drug Dev Ind Pharm. 2022; 48(3): 312–26.

3. Kawabata Y, Wada K, Nakatani M, Yamada S, Onoue S. Formulation design for poorly water-soluble drugs based on Biopharmaceutics Classification System: Basic approaches and practical applications. Int J Pharm. 2023; 642: 120082.

4. Shah N, Dureja H, Kalra S. Nanoparticle technology for oral drug delivery: Recent advances and future directions. J Control Release. 2022; 348: 282–95.

5. Shaker DS, Albadr AA. A comprehensive insight into solid lipid nanoparticles for enhanced drug delivery. Pharm Res. 2024; 41(2): 220–35.

6. Porter CJ, Trevaskis NL, Charman WN. Lipid-based formulations as enabling technology for poorly water-soluble drugs. Nat Rev Drug Discov. 2007; 6(3): 231–48.

7. Patel A, Shelat P. Lipid-based drug delivery system: A review. J Pharm Sci Biosci Res. 2020; 10(3): 123–30.

8. Loftsson T, Brewster ME. Pharmaceutical applications of cyclodextrins: basic science and product development. J Pharm Pharmacol. 2010; 62(11): 1607–21.

9. Müller RH, Keck CM. Twenty years of drug nanocrystals: Where are we, and where do we go? Eur J Pharm Biopharm. 2012; 80(1): 1–3.

10. Serajuddin AT. Salt formation to improve drug solubility. Adv Drug Deliv Rev. 2007; 59(7): 603–16.

11. Takano R, Sugano K, Higashida A, Hayashi Y, Machida M, Aso Y, et al. Oral absorption of poorly water-soluble drugs: computer simulation of fraction absorbed in humans from a miniscale dissolution test. Pharm Res. 2006; 23(6): 1144–56.

12. Chen Y, Liu C, Chen Z, Su C, Hageman M, Hussain M, et al. Drug–polymer–water interaction and its implication for the dissolution performance of amorphous solid dispersions. Mol Pharm. 2015; 12(2): 576–89.

13. Vasconcelos T, Sarmento B, Costa P. Solid dispersions as strategy to improve oral bioavailability of poor water-soluble drugs. Drug Discov Today. 2007; 12(23–24): 1068–75.

14. Jermain SV, Brough C, Williams RO. Amorphous solid dispersions and nanocrystal technologies for poorly water-soluble drug delivery—an update. Int J Pharm. 2018; 535(1–2): 379–92.

15. Zhang L, Pornpattananangkul D, Hu CM, Huang CM. Development of nanoparticles for antimicrobial drug delivery. Curr Med Chem. 2010; 17(6): 585–94.

Received on 16.05.2025 Revised on 25.06.2025

Accepted on 26.07.2025 Published on 04.10.2025

Available online from October 10, 2025

Asian J. Res. Pharm. Sci. 2025; 15(4):429-432.

DOI: 10.52711/2231-5659.2025.00064

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Creative Commons License.